Trials / Completed
CompletedNCT06928051
A Study of S-892216 in Participants With COVID-19
Phase 2 Study of S-892216 in Participants Infected With SARS-CoV-2
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 282 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-892216 | S-892216 will be administered orally as a tablet. |
| DRUG | Placebo | Placebo will be administered orally as a tablet. |
Timeline
- Start date
- 2025-06-06
- Primary completion
- 2025-09-22
- Completion
- 2025-09-22
- First posted
- 2025-04-15
- Last updated
- 2025-09-30
Locations
57 sites across 2 countries: United States, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06928051. Inclusion in this directory is not an endorsement.